In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss diagnosis and treatment of MASH using a case-based approach with two master clinicians, one a hepatologist and the other a primary care physician. This special episode is supported by an independent educational […]
Read More
In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is supported by an independent educational grant from Novo. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; […]
Read More
In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with the benefits of Automated Insulin Delivery for people with Type 2 Diabetes with two master clinicians, one an diabetes specialist, the other a primary care doctor. This special episode is supported by an independent educational grant from Insulet. Presented […]
Read More
In this special series on Weight Bias and Stigma our host, Dr. Neil Skolnik will discuss weight bias and stigma and its importance because weight bias and stigma have an important impact the experience of living with obesity, leads to measurable adverse outcomes, and when it is present in health care interactions it affects all […]
Read More
This issue will review: 1. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial 2. Impact of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: Results from the SOUL Randomized Trial 3. The effect of substituting water for artificially sweetened beverages on glycemic […]
Read MoreAbatacept, a cytotoxic T lymphocyte–associated protein 4 immunoglobulin that inhibits T-cell costimulation, was evaluated for 12 months in stage 1 type 1 diabetes (T1D) to delay disease progression. Despite modest preservation of area under the curve C-peptide at 12 months, the primary end point was not met. We adopted the oral minimal model (OMM) to […]
Read MoreType 1 diabetes (T1D) is an autoimmune disease characterized by β-cell destruction promoted by autoreactive T cells. Eukaryotic translation initiation factor 4E (eIF4E)–binding protein 1 (4E-BP1) and 4E-BP2 are translational repressors and downstream targets of mammalian target of rapamycin complex 1 (mTORC1). Activation of the 4E-BP2/eIF4E pathway by 4E-BP2 deletion promotes translation initiation, inducing β-cell […]
Read MoreEarly postprandial glucagon concentrations are higher in type 1 diabetes (T1D) than in individuals with no diabetes (ND). To determine the cause, we infused stable [13C9, 15N1]glucagon before, during, and after a mixed meal in 16 ND and 16 T1D individuals to measure glucagon turnover. In a subcohort of 9 ND and 12 T1D individuals, […]
Read MorePreclinical studies suggest that activating branched-chain amino acid (BCAA) catabolism may improve chronic kidney disease (CKD). In this prospective clinical study, we sought to examine the association between urinary BCAA excretion and risk of CKD progression in patients with type 2 diabetes. Baseline urinary BCAAs were measured by mass spectrometry in 1,868 outpatients with type […]
Read MoreB lymphocytes are thought to drive β-cell destruction in type 1 diabetes (T1D) by activating anti-islet T cells. However, the observation that autoreactive T-cell activation and disease progression can occur without B cells challenges this view. Still, preclinical and clinical studies have shown that B-cell depletion alleviates β-cell destruction, suggesting a critical role for B […]
Read More